BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Recommendation of “Moderate Buy” by Analysts

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) has been given an average recommendation of “Hold” by the twenty-six ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $119.11.

BMRN has been the topic of several research analyst reports. Guggenheim decreased their price target on BioMarin Pharmaceutical from $125.00 to $120.00 in a research note on Thursday, April 27th. Robert W. Baird raised their price target on BioMarin Pharmaceutical from $112.00 to $127.00 in a research report on Thursday, April 27th. BMO Capital Markets decreased their price objective on shares of BioMarin Pharmaceutical from $107.00 to $102.00 and set a “market perform” rating on the stock in a research report on Tuesday, March 7th. Canaccord Genuity Group lowered their price objective on shares of BioMarin Pharmaceutical from $119.00 to $112.00 and set a “hold” rating on the stock in a research note on Tuesday, February 28th. Finally, Citigroup started coverage on shares of BioMarin Pharmaceutical in a report on Tuesday, February 21st. They issued a “neutral” rating and a $116.00 price target on the stock.

BioMarin Pharmaceutical Trading Down 1.6 %

NASDAQ:BMRN opened at $90.54 on Thursday. BioMarin Pharmaceutical has a 12-month low of $70.73 and a 12-month high of $117.77. The company has a current ratio of 4.75, a quick ratio of 3.21 and a debt-to-equity ratio of 0.23. The stock’s 50 day simple moving average is $94.92 and its 200-day simple moving average is $100.02. The firm has a market cap of $16.99 billion, a P/E ratio of 238.26 and a beta of 0.38.

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) last issued its earnings results on Monday, February 27th. The biotechnology company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.01). The firm had revenue of $537.54 million during the quarter, compared to analysts’ expectations of $533.88 million. BioMarin Pharmaceutical had a net margin of 3.30% and a return on equity of 4.02%. Equities analysts anticipate that BioMarin Pharmaceutical will post 1.06 EPS for the current year.

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, Director V Bryan Lawlis sold 8,500 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $97.09, for a total transaction of $825,265.00. Following the transaction, the director now directly owns 28,950 shares of the company’s stock, valued at $2,810,755.50. The sale was disclosed in a filing with the SEC, which is available at this link. In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 30,000 shares of the stock in a transaction that occurred on Wednesday, May 10th. The shares were sold at an average price of $94.85, for a total value of $2,845,500.00. Following the completion of the sale, the chief executive officer now owns 426,213 shares of the company’s stock, valued at $40,426,303.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director V Bryan Lawlis sold 8,500 shares of the business’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $97.09, for a total transaction of $825,265.00. Following the transaction, the director now directly owns 28,950 shares in the company, valued at $2,810,755.50. The disclosure for this sale can be found here. Insiders have sold a total of 81,500 shares of company stock worth $7,735,465 in the last three months. 1.84% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Services Advisors Inc. lifted its position in shares of BioMarin Pharmaceutical by 225.9% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 16,838 shares of the biotechnology company’s stock worth $1,298,000 after purchasing an additional 11,672 shares during the last quarter. American Century Companies Inc. lifted its holdings in BioMarin Pharmaceutical by 64.6% during the 1st quarter. American Century Companies Inc. now owns 11,312 shares of the biotechnology company’s stock worth $872,000 after buying an additional 4,440 shares during the last quarter. Cetera Advisor Networks LLC lifted its holdings in BioMarin Pharmaceutical by 38.3% during the 1st quarter. Cetera Advisor Networks LLC now owns 5,525 shares of the biotechnology company’s stock worth $426,000 after buying an additional 1,530 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of BioMarin Pharmaceutical by 14.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,362 shares of the biotechnology company’s stock worth $644,000 after acquiring an additional 1,055 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of BioMarin Pharmaceutical by 395.4% in the 1st quarter. Acadian Asset Management LLC now owns 431 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 344 shares during the last quarter. 96.26% of the stock is currently owned by hedge funds and other institutional investors.

About BioMarin Pharmaceutical

(Get Rating)

BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.